Nephrogenic systemic fibrosis.
There seems to be an association between exposure to intravenous gadolinium-based contrast agents (GBCAs) and nephrogenic systemic fibrosis (NSF), a debilitating and sometimes fatal disease. This article addresses the relationship between GBCAs and NSF and answers some common questions. The policy deployed at Yale-New Haven Hospital for prevention of NSF and screening for patients at risk is delineated and discussed along with recommendations by the Food and Drug Administration.
Department of Diagnostic Radiology, Yale University School of Medicine, 333 Cedar Street, P.O. Box 208042, New Haven, CT 06520-5913, USA. jeffrey.weinreb@yale.edu
Jeffrey C
JC
Weinreb
Phillip H
PH
Kuo
D003287:Contrast Media / Q000009:adverse effects*; D005682:Gadolinium / Q000009:adverse effects*; D005919:Glomerular Filtration Rate; D006801:Humans; D008279:Magnetic Resonance Imaging / Q000379:methods*; D054989:Nephrogenic Fibrosing Dermopathy / Q000139:chemically induced* / Q000517:prevention & control*; D012307:Risk Factors
D003287:Contrast Media; D005682:Gadolinium